Apogee Therapeutics chief medical officer sells shares value $191,739

Carl Dambkowski, the Chief Medical (TASE:PMCN) Officer of Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE), a $2.68 billion biotech firm, not too long ago executed important inventory transactions. In keeping with a latest submitting, Dambkowski offered a complete of 4,085 shares of Apogee Therapeutics’ widespread inventory on January 2, 2025. The shares had been offered in a number of transactions at costs starting from $46.42 to $47.92, totaling roughly $191,739. The inventory has proven exceptional power, delivering a 69% return over the previous 12 months. In keeping with InvestingPro evaluation, analysts preserve a Sturdy Purchase ranking with worth targets starting from $80 to $110.

Along with the gross sales, Dambkowski acquired 1,360 shares via a inventory choice train at $22.86 per share. Following these transactions, he holds 255,348 shares within the firm. The gross sales had been performed below a pre-established Rule 10b5-1 buying and selling plan. InvestingPro subscribers can entry further insights, together with 8 extra key recommendations on APGE’s monetary well being and progress prospects.

In different latest information, Apogee Therapeutics has reported encouraging outcomes from its ongoing Part 1 medical trial of APG777, a remedy for moderate-to-severe atopic dermatitis, exhibiting a positive security profile and sustained biomarker inhibition for as much as 9 months. Guggenheim and Stifel have maintained their Purchase scores on Apogee, with Guggenheim elevating the value goal to $110 from the earlier $95, based mostly on the corporate’s promising analysis and growth technique. The corporate has additionally initiated a Part 1 trial for APG990, with interim information anticipated in 2025. By way of company progress, Jeff S. Hartness has been appointed as the brand new Chief Business Officer, and Dr. Lisa Bollinger has joined the board of administrators. Guggenheim’s analyst emphasised that latest trial failures by rivals underscore the potential of Apogee’s technique, which focuses on monoclonal antibodies that concentrate on clinically validated epitopes. The atopic dermatitis market is projected to develop to roughly $30 billion by 2035, practically quadrupling in measurement, pushed by a rise in sufferers receiving remedy. The corporate maintains a powerful monetary place with a present ratio of 16.39 and additional cash than debt on its steadiness sheet. These are the latest developments at Apogee Therapeutics.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.